Reported research findings
- No established human clinical trials define efficacy or safety for this analog in people to date; reported effects come from mechanism and research-community use.
MUSCLE, GROWTH & RECOVERY
IGF-1 LR3
A long-acting, highly bioavailable analog of natural IGF-1, the primary downstream anabolic mediator of growth hormone.
IGF-1 LR3 is a long-acting analog of natural IGF-1, the primary downstream mediator of growth hormone and a powerful anabolic signal for muscle repair and growth. It is widely used in performance research, though its evidence base rests on mechanism and real-world use rather than human clinical trials.
Why BLP features IGF-1 LR3
Included as a mechanistically powerful compound with an established performance-research following. Human clinical trial evidence is minimal, so despite widespread use it is presented as experimental—popularity does not substitute for documented human trials.
Mechanism
Binds IGF-1 receptors, stimulating muscle satellite-cell activation, protein synthesis, and hyperplasia (new muscle fibers).
The LR3 modification prevents binding to IGF binding proteins, substantially increasing bioavailability.
WHAT THE RESEARCH MEASURED
Research findings
Findings describe study outcomes, not expected personal results.
Preclinical findings
- Reported rapid lean-muscle gains and improved muscle fullness in research use.
- Reported enhanced recovery and reduced soreness; localized growth when injected into specific muscles.
- Dose-dependent effects noted, with possible hypoglycemia, water retention, or joint discomfort; researchers typically start low to assess tolerance.
Regulatory status
IGF-1 LR3 is investigational with minimal human clinical evidence. Sold and offered strictly for laboratory and research use.